Matched-pair analysis of mCRPC patients receiving 177Lu-labeled PSMA-targeted radioligand therapy in a 4-week versus 6-week treatment interval
Intensifying treatment intervals from 6 weeks to 4 weeks showed some improvements in PSA response and PSA-PFS for mCRPC patients, but did not significantly affect OS. Additionally, bone marrow reserve was significantly reduced with the intensified regimen. Therefore, the overall benefit remains uncertain, and further prospective studies are needed to compare 4-week and 6-week intervals regarding toxicity, treatment response, and outcome.
Authors
- Robert Tauber (ORCID: https://orcid.org/0000-0002-4770-3307)
- Matthias Heck (ORCID: https://orcid.org/0000-0002-5754-0628)
- Isabel Rauscher (ORCID: https://orcid.org/0000-0003-4655-2153)
- Calogero D’Alessandria (ORCID: https://orcid.org/0000-0003-2381-1212)
- Wolfgang Weber (ORCID: https://orcid.org/0000-0002-7854-4345)
- Amir Karimzadeh (ORCID: https://orcid.org/0000-0002-7055-8275)
- Matthias Eiber (ORCID: https://orcid.org/0000-0003-2654-6872)
- Charlotte-Sophie Hecker
Institutions
- Universität Hamburg (DE)
- University Medical Center Hamburg-Eppendorf (DE)
- Technical University of Munich (DE)
Publication Details
- Journal
- EJNMMI Research
- Published
- 2024-10-14
- DOI
- https://doi.org/10.1186/s13550-024-01143-0
- Citations
- 2
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.84